Reduced-intensity Allogeneic Stem Cell Transplantation for Co-emergence of Chemotherapy-refractory Follicular Lymphoma and Therapy-related Myelodysplastic Syndrome

Overview

Journal Case Rep Oncol

Publisher Karger

Specialty Oncology

Date 2014 Apr 22

PMID 24748869

Authors

Yuji Shimura

Junya Kuroda

Nana Sasaki

Hitoji Uchiyama

Muneo Ohshiro

Yayoi Matsumura

Hisao Nagoshi

Shinsuke Mizutani

Tsutomu Kobayashi

Yosuke Matsumoto

Shigeo Horiike

Masafumi Taniwaki

Affiliations

Soon will be listed here.

Abstract

A 54-year-old male was diagnosed with follicular lymphoma in September 2003. Despite multiple chemotherapies, including autologous hematopoietic stem cell transplantation (HSCT) with high-dose chemotherapy, the disease eventually relapsed. Additionally, bone marrow analysis revealed the co-emergence of therapy-related myelodysplastic syndrome (t-MDS) in February 2012. In March 2012, we performed related allogeneic HSCT for the treatment of both malignancies. This strategy was successful and the patient has remained free from both malignancies for 23 months. Allogeneic HSCT is a potent curative therapeutic option for both t-MDS and refractory follicular lymphoma.

References

Russell J, Irish W, Balogh A, Chaudhry M, Savoie M, Turner A . The addition of 400 cGY total body irradiation to a regimen incorporating once-daily intravenous busulfan, fludarabine, and antithymocyte globulin reduces relapse without affecting nonrelapse mortality in acute myelogenous leukemia. Biol Blood Marrow Transplant. 2009; 16(4):509-14. DOI: 10.1016/j.bbmt.2009.11.017. View

Cheson B, Rummel M . Bendamustine: rebirth of an old drug. J Clin Oncol. 2009; 27(9):1492-501. DOI: 10.1200/JCO.2008.18.7252. View

Yuji K, Miyakoshi S, Kato D, Miura Y, Myojo T, Murashige N . Reduced-intensity unrelated cord blood transplantation for patients with advanced malignant lymphoma. Biol Blood Marrow Transplant. 2005; 11(4):314-8. DOI: 10.1016/j.bbmt.2005.01.012. View

Tarella C, Passera R, Magni M, Benedetti F, Rossi A, Gueli A . Risk factors for the development of secondary malignancy after high-dose chemotherapy and autograft, with or without rituximab: a 20-year retrospective follow-up study in patients with lymphoma. J Clin Oncol. 2010; 29(7):814-24. DOI: 10.1200/JCO.2010.28.9777. View

Smith S, Le Beau M, Huo D, Karrison T, Sobecks R, Anastasi J . Clinical-cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia: the University of Chicago series. Blood. 2003; 102(1):43-52. DOI: 10.1182/blood-2002-11-3343. View

Zimmerman Z, Scott B, Gopal A, Sandmaier B, Maloney D, Deeg H . Allogeneic hematopoietic cell transplantation in patients with myelodysplastic syndrome and concurrent lymphoid malignancy. Bone Marrow Transplant. 2011; 47(6):804-9. PMC: 3237793. DOI: 10.1038/bmt.2011.180. View

Carney D, Westerman D, Tam C, Milner A, Prince H, Kenealy M . Therapy-related myelodysplastic syndrome and acute myeloid leukemia following fludarabine combination chemotherapy. Leukemia. 2010; 24(12):2056-62. DOI: 10.1038/leu.2010.218. View

Spina F, Alessandrino P, Milani R, Bonifazi F, Bernardi M, Luksch R . Allogeneic stem cell transplantation in therapy-related acute myeloid leukemia and myelodysplastic syndromes: impact of patient characteristics and timing of transplant. Leuk Lymphoma. 2011; 53(1):96-102. DOI: 10.3109/10428194.2011.603445. View

Rummel M, Niederle N, Maschmeyer G, Banat G, von Grunhagen U, Losem C . Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet. 2013; 381(9873):1203-10. DOI: 10.1016/S0140-6736(12)61763-2. View

10.

Leone G, Fianchi L, Voso M . Therapy-related myeloid neoplasms. Curr Opin Oncol. 2011; 23(6):672-80. DOI: 10.1097/CCO.0b013e32834bcc2a. View

11.

Greenberg P, Cox C, LeBeau M, Fenaux P, Morel P, Sanz G . International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997; 89(6):2079-88. View

12.

Thomson K, Morris E, Milligan D, Parker A, Hunter A, Cook G . T-cell-depleted reduced-intensity transplantation followed by donor leukocyte infusions to promote graft-versus-lymphoma activity results in excellent long-term survival in patients with multiply relapsed follicular lymphoma. J Clin Oncol. 2010; 28(23):3695-700. DOI: 10.1200/JCO.2009.26.9100. View

13.

Duong V, Lancet J, Alrawi E, Al-Ali N, Perkins J, Field T . Outcome of azacitidine treatment in patients with therapy-related myeloid neoplasms with assessment of prognostic risk stratification models. Leuk Res. 2013; 37(5):510-5. DOI: 10.1016/j.leukres.2012.12.012. View

14.

Litzow M, Tarima S, Perez W, Bolwell B, Cairo M, Camitta B . Allogeneic transplantation for therapy-related myelodysplastic syndrome and acute myeloid leukemia. Blood. 2009; 115(9):1850-7. PMC: 2832815. DOI: 10.1182/blood-2009-10-249128. View

15.

Morton L, Dores G, Tucker M, Kim C, Onel K, Gilbert E . Evolving risk of therapy-related acute myeloid leukemia following cancer chemotherapy among adults in the United States, 1975-2008. Blood. 2013; 121(15):2996-3004. PMC: 3624944. DOI: 10.1182/blood-2012-08-448068. View

16.

Freedman A . Follicular lymphoma: 2012 update on diagnosis and management. Am J Hematol. 2012; 87(10):988-95. DOI: 10.1002/ajh.23313. View

17.

Vardiman J, Thiele J, Arber D, Brunning R, Borowitz M, Porwit A . The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009; 114(5):937-51. DOI: 10.1182/blood-2009-03-209262. View

18.

Montoto S, Corradini P, Dreyling M, Ghielmini M, Kimby E, Lopez-Guillermo A . Indications for hematopoietic stem cell transplantation in patients with follicular lymphoma: a consensus project of the EBMT-Lymphoma Working Party. Haematologica. 2013; 98(7):1014-21. PMC: 3696603. DOI: 10.3324/haematol.2013.084723. View

19.

Tobinai K, Ishizawa K, Ogura M, Itoh K, Morishima Y, Ando K . Phase II study of oral fludarabine in combination with rituximab for relapsed indolent B-cell non-Hodgkin lymphoma. Cancer Sci. 2009; 100(10):1951-6. PMC: 11159842. DOI: 10.1111/j.1349-7006.2009.01247.x. View